Cargando…

DIPG-09. Diffuse Midline Glioma-Adaptive Combinatory Trial (DMG-ACT): A biology-driven platform trial in pediatric and young adult patients with diffuse midline glioma

BACKGROUND: Despite advances in our understanding of the biology of diffuse midline gliomas (DMGs), little progress has been made in improving outcomes. Therapy development is limited by lack of preclinical data across multiple model systems and laboratories; limited knowledge about blood-brain barr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franson, Andrea, Kline, Cassie, Molinaro, Annette, Zhang, Yalan, Hitchner, Kelly, Koschmann, Carl, Nazarian, Javad, Mueller, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Diffuse Midline Glioma/DIPG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164735/ http://dx.doi.org/10.1093/neuonc/noac079.066

Ejemplares similares

DIPG-06. Uncovering the FACTs in Diffuse Midline Glioma (DMG)
por: Holliday, Holly, et al.
Publicado: (2022)

DIPG-45. Radiation induces a robust interferon response in Diffuse Midline Glioma (DMG), improving the potential for combination immunotherapy
por: Minns, Hanna E, et al.
Publicado: (2022)

DIPG-39. New preclinical models for Diffuse Midline Glioma
por: Klenner, Marbod, et al.
Publicado: (2022)

DIPG-64. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS
por: Przystal*, Justyna M, et al.
Publicado: (2020)

DIPG-17. BIOPSY-PROVEN DIFFUSE MIDLINE GLIOMA IN ADOLESCENTS AND YOUNG ADULTS
por: Tanaka, Shota, et al.
Publicado: (2020)

DIPG-04. THERAPEUTIC STRATEGY FOR DIFFUSE MIDLINE GLIOMAS. A SINGLE CENTER EXPERIENCE
por: Yamanaka, Takumi, et al.
Publicado: (2020)

DIPG-31. MOLECULAR MECHANISMS AND FUNCTIONAL IMPACT OF ABERRANT SPLICING IN DIFFUSE MIDLINE GLIOMAS
por: Naqvi, Ammar, et al.
Publicado: (2020)

DIPG-49. International preclinical drug discovery and biomarker program informing an adoptive combinatorial trial for DMG
por: Nazarian, Javad, et al.
Publicado: (2022)

DIPG-42. Diffuse midline gliomas, H3K27-altered as an interdisciplinary challenge
por: Kammler, Gertrud, et al.
Publicado: (2022)

DIPG-61. Preclinical efficacy of combined radiotherapy with venetoclax treatment in targeting diffuse midline gliomas
por: Madhavan, Krishna, et al.
Publicado: (2022)

DIPG-10. A Phase I trial of panobinostat following radiation therapy in children with diffuse intrinsic pontine glioma (DIPG) or H3K27M-mutated thalamic diffuse midline glioma (DMG): Report from the Pediatric Brain Tumor Consortium (PBTC-047)
por: Monje, Michelle, et al.
Publicado: (2022)

DIPG-48. MRI volumetric and machine learning based analyses predict survival outcome in pediatric diffuse midline glioma
por: Bonner, Erin R, et al.
Publicado: (2022)

DIPG-58. HISTONE H3 WILD-TYPE DIPG/DMG OVEREXPRESSING EZHIP EXTEND THE SPECTRUM OF DIFFUSE MIDLINE GLIOMAS WITH PRC2 INHIBITION BEYOND H3-K27M MUTATION
por: Castel, David, et al.
Publicado: (2020)

DIPG-47. TSO500ctDNA sequencing reveals oncogenic mutations and copy number variations in the liquid biome of children with diffuse midline glioma
por: Bonner, Erin R, et al.
Publicado: (2022)

DIPG-47. HISTONE MUTATIONS ENHANCE RAS MEDIATED ERK5 GROWTH SIGNALING IN DIFFUSE MIDLINE GLIOMAS
por: Stanton, Ann-Catherine, et al.
Publicado: (2020)

DIPG-44. H3K27-altered diffuse midline gliomas with secondary driver molecular alterations
por: Gestrich, Catherine, et al.
Publicado: (2022)

DIPG-37. PREDICTING OUTCOME IN CHILDHOOD DIFFUSE MIDLINE GLIOMAS USING MAGNETIC RESONANCE IMAGING BASED TEXTURE ANALYSIS
por: Szychot, Elwira, et al.
Publicado: (2020)

DIPG-40. Combined pharmacological and genetic screening to identify dependencies and combinations in ACVR1-mutant diffuse midline glioma
por: Rogers, Rebecca, et al.
Publicado: (2022)

DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells
por: Monje, Michelle, et al.
Publicado: (2022)

DIPG-34. SUPER ELONGATION COMPLEX AS A TARGETABLE DEPENDENCY IN H3K27M+ DIFFUSE MIDLINE GLIOMA
por: Dahl, Nathan, et al.
Publicado: (2020)

DIPG-19. TARGETING ATM MUTATION IN METASTATIC DIFFUSE MIDLINE GLIOMA – A CASE OF SUSTAINED RESPONSE USING PARP INHIBITOR
por: Tsui, Karen, et al.
Publicado: (2020)

DIPG-56. Development and application of a novel antibody against CD99 as a therapeutic strategy in Diffuse Midline Glioma
por: Venkataraman, Sujatha, et al.
Publicado: (2022)

DIPG-78. REVERTANCE OF THE H3K27M MUTATION RESCUES CHROMATIN MARKS NECESSARY FOR ONCOGENESIS IN DIFFUSE MIDLINE GLIOMA
por: Nesvick, Cody, et al.
Publicado: (2020)

DIPG-50. Bioinformatic evaluation of genes involved in sphingomyelin biosynthesis in Diffuse Midline Glioma H3K27 altered/DIPG: dysregulation of sphingosine 1-phosphate (SP1)
por: Humphreys, Aimee, et al.
Publicado: (2022)

DIPG-75. PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM
por: Khuong-Quang, Dong-Anh, et al.
Publicado: (2020)

DIPG-38. Significant tumor regression of H3K27M-mutated diffuse midline glioma of the brainstem with panobinostat: a case report.
por: Partap, Sonia, et al.
Publicado: (2022)

DIPG-76. HISTONE H3 PHOSPHORYLATION IN H3K27M MIDLINE GLIOMAS
por: Zhang, Liang, et al.
Publicado: (2020)

DIPG-66. FEASIBILITY AND APPLICABILITY OF MOLECULAR GUIDED THERAPY IN HIGH GRADE GLIOMA/DIFFUSE MIDLINE GLIOMA: RESULTS FROM BEAT CHILDHOOD CANCER NMTRC-009 MOLECULAR GUIDED THERAPY STUDY
por: Harrod, Virginia, et al.
Publicado: (2020)

DIPG-41. DISSECTING THE MECHANISTIC BASIS FOR ACVR1 AND PIK3CA MUTATION CO-OCCURRENCE IN DIFFUSE MIDLINE GLIOMAS USING GENETICALLY ENGINEERED MOUSE MODELS
por: Wu, Annette, et al.
Publicado: (2020)

DIPG-40. TARGETING MASTER REGULATOR DEPENDENCIES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Pavisic, Jovana, et al.
Publicado: (2020)

DIPG-01. REIRRADIATION PRACTICES FOR DIFFUSE INTRINSIC PONTINE GLIOMA
por: Cacciotti, Chantel, et al.
Publicado: (2020)

DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG
por: Gardner, Sharon, et al.
Publicado: (2020)

DIPG-51. ACVR1 MUTATIONS PROMOTE TUMOR GROWTH IN MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Adorno, Jennifer Ocasio, et al.
Publicado: (2020)

DIPG-84. COMPLEMENTARY AND ALTERNATIVE MEDICINE IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: El-Khouly, Fatma, et al.
Publicado: (2020)

DIPG-10. OPTIMAL HDAC INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Vitanza, Nicholas, et al.
Publicado: (2020)

DIPG-32. AKT SIGNALING DRIVES RESISTANCE TO ONC201 IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Jackson, Evangeline R, et al.
Publicado: (2020)

DIPG-27. Behavioral disturbances as underestimated presenting symptoms in children with Diffuse Intrinsic Pontine Glioma (DIPG)
por: Milanaccio, Claudia, et al.
Publicado: (2022)

DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS)
por: Khadka, Prasidda, et al.
Publicado: (2020)

DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Khan, Aaminah, et al.
Publicado: (2020)

DIPG-77. TREATMENT EXTENT AND THE EFFECT ON SURVIVAL IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Baugh, Joshua, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rtlc85r8nv3ctq35cecie9eapk